| Recruiting | OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites NCT06856603 | National Medical Research Radiological Centre of the Ministry of Health of Russia | Phase 2 |
| Completed | The Role of Surgery for Esophageal Cancer With Metastatic Disease (M1) NCT06424210 | National Taiwan University Hospital | — |
| Completed | Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia NCT05789771 | Blokhin's Russian Cancer Research Center | — |
| Completed | MAnagement of METastatic Disease in Campania (MAMETIC) NCT04595032 | National Cancer Institute, Naples | — |
| Unknown | Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial NCT05188911 | Fudan University | — |
| Unknown | The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies NCT04492735 | Roshni Dasgupta | — |
| Terminated | Safety and Targeting of Anti-hk2 Antibody in mCRPC NCT04116164 | SpectronRX | EARLY_Phase 1 |
| Terminated | IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study NCT03705403 | Maastricht University Medical Center | Phase 2 |
| Completed | Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patient NCT03823989 | Lipomedix Pharmaceuticals Inc. | Phase 1 |
| Unknown | Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery NCT03632005 | John Street | N/A |
| Withdrawn | Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients NCT01861938 | Hadassah Medical Organization | Phase 2 / Phase 3 |
| Withdrawn | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) NCT02856867 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Terminated | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer NCT02795819 | Virginia Commonwealth University | Phase 1 |
| Completed | Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary NCT02628379 | Foundation Medicine | — |
| Withdrawn | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or NCT02496832 | University Health Network, Toronto | N/A |
| Terminated | Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation NCT02175654 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 2 |
| Terminated | CPCT-05 Biopsy Protocol Patient Selection NCT01904916 | P.O. Witteveen | N/A |
| Completed | Stereotactic Radiation Therapy for Pediatric Sarcomas NCT01763970 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer NCT01875380 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Phase 2 |
| Completed | Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the NCT01703910 | Centro Nacional de Investigaciones Oncologicas CARLOS III | Phase 2 |
| Terminated | BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer NCT01679405 | Johannes Gutenberg University Mainz | Phase 1 |
| Terminated | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy NCT01484860 | University Health Network, Toronto | Phase 2 |
| Completed | CPCT-02 Biopsy Protocol NCT01855477 | Foundation CPCT | N/A |
| Terminated | Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy NCT01450683 | Stanford University | Phase 2 |
| Terminated | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer NCT01020305 | Sandy Srinivas | Phase 1 / Phase 2 |
| Terminated | Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Pat NCT01089595 | Fox Chase Cancer Center | Phase 2 |
| Completed | Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors NCT00369785 | Wake Forest University Health Sciences | Phase 3 |
| Completed | Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney R NCT00480389 | University Health Network, Toronto | Phase 2 |
| Completed | Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in NCT00609401 | Italian Trial in Medical Oncology | Phase 2 |
| Completed | Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, NCT00678158 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen NCT00532454 | National Cancer Center, Korea | Phase 2 |
| Unknown | Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma NCT00406900 | Ludwig-Maximilians - University of Munich | — |